1. Home
  2. RNXT vs INTS Comparison

RNXT vs INTS Comparison

Compare RNXT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • INTS
  • Stock Information
  • Founded
  • RNXT 2012
  • INTS 2012
  • Country
  • RNXT United States
  • INTS United States
  • Employees
  • RNXT N/A
  • INTS N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNXT Health Care
  • INTS Health Care
  • Exchange
  • RNXT Nasdaq
  • INTS Nasdaq
  • Market Cap
  • RNXT 31.6M
  • INTS 33.4M
  • IPO Year
  • RNXT 2021
  • INTS 2023
  • Fundamental
  • Price
  • RNXT $1.04
  • INTS $2.11
  • Analyst Decision
  • RNXT Strong Buy
  • INTS Strong Buy
  • Analyst Count
  • RNXT 1
  • INTS 3
  • Target Price
  • RNXT $9.00
  • INTS $8.50
  • AVG Volume (30 Days)
  • RNXT 242.7K
  • INTS 33.1K
  • Earning Date
  • RNXT 03-31-2025
  • INTS 03-13-2025
  • Dividend Yield
  • RNXT N/A
  • INTS N/A
  • EPS Growth
  • RNXT N/A
  • INTS N/A
  • EPS
  • RNXT N/A
  • INTS N/A
  • Revenue
  • RNXT N/A
  • INTS N/A
  • Revenue This Year
  • RNXT N/A
  • INTS N/A
  • Revenue Next Year
  • RNXT N/A
  • INTS N/A
  • P/E Ratio
  • RNXT N/A
  • INTS N/A
  • Revenue Growth
  • RNXT N/A
  • INTS N/A
  • 52 Week Low
  • RNXT $0.77
  • INTS $1.50
  • 52 Week High
  • RNXT $1.86
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 32.70
  • INTS 41.98
  • Support Level
  • RNXT $1.00
  • INTS $1.84
  • Resistance Level
  • RNXT $1.18
  • INTS $2.53
  • Average True Range (ATR)
  • RNXT 0.10
  • INTS 0.32
  • MACD
  • RNXT -0.04
  • INTS -0.02
  • Stochastic Oscillator
  • RNXT 8.00
  • INTS 37.50

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: